

**Ruthenium(II) complex containing cinamic acid derivative
inhibits cell cycle progression at G0/G1 and induces apoptosis
in melanoma cells**

Amanda Alvim Negreti^a, Guilherme Álvaro Ferreira-Silva^a, Carolina Girotto Pressete^a, Rafael Fonseca Miranda^a, Caio C. Candido^b, Angelica E. Graminha^c, Antonio Carlos Doriguetto^b, Ester Siqueira Caixeta^a, João Adolfo Costa Hanemann^d, Angel Maurício Castro Gamero^e, Marilia I. F. Barbosa^{*b}, Marta Miyazawa^{*d}, Marisa Ionta^{*a}

^aInstitute of Biomedical Sciences, Federal University of Alfenas, zip-code 37130-001, Alfenas, MG, Brazil

^bInstitute of Chemistry, Federal University of Alfenas, zip-code 37130-001, Alfenas, MG, Brazil

^cDepartment of Chemistry, Federal University of São Carlos, zip code 13565-905, São Carlos, SP, Brazil

^dDepartment of Clinic and Surgery, School of Dentistry. Federal University of Alfenas, zip-code 37130-001, Alfenas, MG, Brazil

^eHuman Genetics Laboratory, Institute of Natural Science, Federal University of Alfenas, Alfenas, MG, Brazil

*Corresponding author: Marisa Ionta, Marta Miyazawa and Marilia I.F. Barbosa

E-mail addresses: marisa.ionta@unifal-mg.edu.br; marta.miyazawa@unifal-mg.edu.br; mariliaifrazaob@yahoo.com.br

SUMMARY

Figure S1. $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S2. $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S3. $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S4. ^1H spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S5. ^1H spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S6. ^1H spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S7. $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S8. $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S9. $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$

Figure S10: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d6

Figure S11: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d6

Figure S12: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d6

Figure S13. IR spectrum of (A) L_1 and (B) $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.

Figure S14. IR spectrum of (A) L_2 and (B) $[\text{Ru}(L_2)(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.

Figure S15. IR spectrum of (A) L_3 and (B) $[\text{Ru}(L_3)(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.

Figure S16. UV-Vis spectrum of $[\text{Ru}(L_1)(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .

Figure S17. UV-Vis spectrum of $[\text{Ru}(L_2)(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .

Figure S18. UV-Vis spectrum of $[\text{Ru}(L_3)(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .

Figure S19. cyclic voltammogram of (A) $[\text{Ru}(L_1)(\text{dppb})(\text{bipy})]\text{PF}_6$, (B) $[\text{Ru}(L_2)(\text{dppb})(\text{bipy})]\text{PF}_6$, (C) $[\text{Ru}(L_3)(\text{dppb})(\text{bipy})]\text{PF}_6$.

Figure S20. Cell viability determined by MTS assay in HT-144 cell line after 24 h of the treatment with ligands L_1 , L_2 or L_3 .

Figure S21. Cell viability determined by Trypan blue exclusion assay in CHL-1 cell line after 24 h of the treatment with $[\text{Ru}(L_2)(\text{dppb})(\text{bipy})]\text{PF}_6$ (complex **2**).

Table 1S. chemical shifts and coupling constants of the complexes

Table 2S. IR frequencies

Table 3S. Electrochemical potentials of the complexes

Table 4S. Selectivity indexes using CCD-1059Sk as reference of non-tumor cells.

Table 5S. Selectivity indexes using FB1 as reference of non-tumor cells.

Table 6S. Selectivity indexes using NGM as reference of non-tumor cells.

20210313 mmic 10
mmic 10 com dms
p
CDCL3

~53.50
~53.22
~50.79
~50.51




Figure S1: $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CH_2Cl_2 .

20210113 cbaccf3
cbaccf3 lavado 2 a missão
p
d2o

~51.49
~51.21
~49.05
~48.77




Figure S2: $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CH_2Cl_2 .




Figure S3: $^{31}\text{P}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CH_2Cl_2 .




Figure S4: ^1H spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S5: ^1H spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S6: ^1H spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S7: $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S8: $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S9: $^{13}\text{C}\{^1\text{H}\}$ spectrum of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$, in CDCl_3 .




Figure S10: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_1)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d_6




Figure S11: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_2)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d_6




Figure S12: $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy of $[\text{Ru}(\text{L}_3)(\text{dppb})(\text{bipy})]\text{PF}_6$: 0 min., 24 h and 48 h, in DMSO-d_6




Figure S13: IR spectrum of (A) L1 ligand and (B) $[\text{Ru}(\text{L1})(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.




Figure S14: IR spectrum of (A) L2 ligand and (B) $[\text{Ru}(\text{L2})(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.




Figure S15: IR spectrum of (A) L3 ligand and (B) $[\text{Ru}(\text{L3})(\text{dppb})(\text{bipy})]\text{PF}_6$ in KBr.




Figure S16: UV-Vis spectrum of $[\text{Ru}(\text{L1})(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .




Figure S17: UV-Vis spectrum of $[\text{Ru}(\text{L2})(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .




Figure S18: UV-Vis spectrum of $[\text{Ru}(\text{L3})(\text{dppb})(\text{bipy})]\text{PF}_6$ in CH_2Cl_2 .






Figure S19: cyclic voltammogram of (A) $[\text{Ru}(\text{L1})(\text{dppb})(\text{bipy})]\text{PF}_6$, (B) $[\text{Ru}(\text{L2})(\text{dppb})(\text{bipy})]\text{PF}_6$, (C) $[\text{Ru}(\text{L3})(\text{dppb})(\text{bipy})]\text{PF}_6$

HT-144




Figure S20. Cell viability determined by MTS assay in HT-144 cell line after 24 h of the treatment with ligands L₁, L₂ or L₃.




Figure S21. Cell viability determined by Trypan blue exclusion assay in CHL-1 cell line after 24 h of the treatment with complex (2). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to control group (DMSO).

Table 1S. chemical shifts and coupling constants of the complexes

| Compound | δ $^{31}\text{P}\{\text{H}\}$ (ppm) | $^2\text{J}_{\text{p-p}}$ (Hz) |
|--|--|--------------------------------|
| [RuCl ₂ (dppb)(bipy)] | 41.5 / 32.8 | 30.0 |
| [Ru(L ₁)(dppb)(bipy)]PF ₆ | 53.4 / 50.6 | 38.2 |
| [Ru(L ₂)(dppb)(bipy)]PF ₆ | 45.5 / 46.0 | 36.8 |
| [Ru(L ₃)(dppb)(bipy)]PF ₆ | 48.7 / 46.2 | 38.2 |

Table 2S. IR carboxylate and counter ion stretching frequencies

| Compound | vas(COO ⁻) | vs(COO ⁻) | $\Delta\nu$ | vsP-F |
|--|------------------------|-----------------------|--|-------|
| | | | (vas(COO ⁻) - vs(COO ⁻)) | |
| [RuCl ₂ (dppb)(bipy)] | - | - | - | - |
| [Ru(L ₁)(dppb)(bipy)]PF ₆ | 1705 | 1257 | 448 | 847 |
| L ₁ | 1690 | 1318 | 372 | - |
| [Ru(L ₂)(dppb)(bipy)]PF ₆ | 1632 | 1290 | 342 | 832 |
| L ₂ | 1684 | 1322 | 362 | - |
| [Ru(L ₃)(dppb)(bipy)]PF ₆ | 1674 | 1249 | 425 | 839 |
| L ₃ | 1682 | 1310 | 372 | - |

Table 3S. Electrochemical potentials of the complexes

| Compound | Ru(II)/Ru(III) (V) | Ru(III)/Ru(II) (V) | E _{1/2} (V) |
|--|--------------------|--------------------|----------------------|
| [RuCl ₂ (dppb)(bipy)] | 0.62 | 0.57 | 0.6 |
| [Ru(L ₁)(dppb)(bipy)]PF ₆ | 1.45 | 1.40 | 1.4 |
| [Ru(L ₂)(dppb)(bipy)]PF ₆ | 1.35 | 1.29 | 1.3 |
| [Ru(L ₃)(dppb)(bipy)]PF ₆ | 1.34 | 1.28 | 1.3 |

Table 4S. Selectivity indexes (SIs) determined using CCD-1059Sk (fibroblast derived from human normal skin) as reference of non-tumor cell line.

| Cell line | CINAM | TRANSCINAM | COLOROCINAM |
|------------|-------------|-------------|-------------|
| HT-144 | 2.46 | 2.97 | 1.79 |
| SK-MEL-147 | 1.64 | 1.50 | 0.76 |
| CHL-1 | 4.63 | 3.30 | 2.37 |
| WM1366 | 0.91 | 1.34 | 1.22 |

Table 5S. Selectivity indexes (SIs) determined using FB1 (fibroblast derived from primary culture established from gingival tissue) as reference of non-tumor cell line.

| Cell line | CINAM | TRANSCINAM | COLOROCINAM |
|------------|-------|-------------|-------------|
| HT-144 | 1.40 | 4.26 | 1.42 |
| SK-MEL-147 | 0.94 | 2.14 | 0.60 |
| CHL-1 | 2.64 | 4.70 | 1.88 |
| WM1366 | 0.52 | 1.91 | 0.97 |

Table 6S. Selectivity indexes (SIs) determined using NGM as reference of non-tumor cell line.

| Cell line | CINAM | TRANSCINAM |
|-------------------|--------------|-------------------|
| HT-144 | 2.82 | 2.32 |
| SK-MEL-147 | 1.88 | 1.16 |
| CHL-1 | 5.31 | 2.5 |
| WM1366 | 1.04 | 1.04 |